An 18‑year‑old woman who stopped depot medroxyprogesterone acetate (DMPA) after long‑term use and switched to a combined oral contraceptive (COC) now has a moderate menstrual flow lasting several weeks; is this expected and how should it be managed?

Management of Prolonged Bleeding After Switching from DMPA to Combined Oral Contraceptives

This prolonged bleeding is an expected consequence of the transition from long-term DMPA use to combined oral contraceptives, and the patient should continue the COC for at least 21 consecutive days before any hormone-free interval to allow endometrial stabilization. 1

Understanding the Underlying Mechanism

• Long-term DMPA use causes profound endometrial atrophy and disrupts normal menstrual patterns, with irregular bleeding occurring in nearly all patients initially and often persisting for 6 months or longer. 2

• The return to normal endometrial function after DMPA discontinuation typically takes 9 to 18 months as the endometrial lining gradually recovers from its atrophic state and ovulatory function resumes. 2

• When switching from DMPA to a COC, the estrogen component must rebuild the endometrium while the progestin provides stability—this process takes time and breakthrough bleeding during the first 3–6 months is common and not harmful. 1

Immediate Management Strategy

• The patient must continue taking the active COC pills daily for at least 21 consecutive days without interruption before considering any hormone-free interval, as premature breaks will perpetuate unstable bleeding. 1

• Add ibuprofen 400–600 mg three times daily for 5–7 days as first-line adjunctive therapy to reduce menstrual blood loss while the endometrium stabilizes. 1

• If the patient has been taking the COC for fewer than 21 days, she should not take a hormone-free interval even if bleeding is bothersome—doing so will worsen the bleeding pattern. 1

Rule Out Other Causes Before Attributing Bleeding to the Transition

• Pregnancy must be excluded with a urine or serum pregnancy test, as contraceptive failure can occur during method transitions. 1

• Screen for sexually transmitted infections (chlamydia and gonorrhea) if the patient has risk factors, as cervicitis can cause irregular bleeding. 1

• Assess for medication interactions (particularly enzyme-inducing drugs like rifampin or certain anticonvulsants), cigarette smoking, and thyroid disorders, all of which can exacerbate breakthrough bleeding. 1

• Consider new uterine pathology (polyps or fibroids) if bleeding persists beyond 3–6 months despite adherence to the COC regimen. 1

Optimizing the COC Regimen

• Ensure the patient is taking a monophasic COC containing 30–35 μg ethinyl estradiol (such as those with levonorgestrel or norgestimate), as these formulations provide the most effective endometrial stabilization and bleeding control. 1

• Counsel the patient that unscheduled bleeding is expected during the first 3–6 months of COC use after DMPA and typically diminishes with continued adherence—this is not a sign of method failure. 1

• If breakthrough bleeding persists after 21 consecutive days of active pills, the patient may take a 3–4 day hormone-free interval to induce a withdrawal bleed, but this should not be done more than once per month. 1

When NSAIDs Are Insufficient

• If NSAIDs for 5–7 days do not control the bleeding and the patient has completed at least 21 days of active pills, consider a brief hormone-free interval (3–4 days) to allow endometrial shedding, then immediately resume active pills. 1

• Extended or continuous COC regimens (taking active pills for 3–4 months without breaks) may ultimately provide better bleeding control once the endometrium has stabilized, but this approach should be deferred until after the initial transition period. 1

Critical Counseling Points to Prevent Discontinuation

• Reassure the patient that this bleeding pattern is a known consequence of the DMPA-to-COC transition and does not indicate that the method is failing or harmful—most women experience resolution within 3–6 months. 1

• Emphasize that premature discontinuation of the COC will not resolve the bleeding, as the underlying issue is the prolonged endometrial recovery from DMPA, which will continue regardless of contraceptive method. 2

• Discuss adherence strategies such as setting daily phone alarms and enlisting family support to ensure the patient takes the pill at the same time every day, as missed pills will worsen breakthrough bleeding. 1

Common Pitfalls to Avoid

• Do not allow the patient to take frequent hormone-free intervals (more than once per month or before completing 21 days of active pills), as this will perpetuate endometrial instability and prolong the bleeding. 1

• Do not switch to a lower-dose estrogen formulation (such as 20 μg ethinyl estradiol pills) during this transition period, as the higher estrogen dose (30–35 μg) is necessary to rebuild the atrophic endometrium. 1

• Do not attribute all bleeding to the contraceptive method without first ruling out pregnancy, infection, and structural pathology—these must be excluded before managing as simple breakthrough bleeding. 1

Expected Timeline for Resolution

• Most patients experience significant improvement in bleeding patterns by 3–6 months of consistent COC use, as the endometrium stabilizes and adapts to the new hormonal environment. 1

• If moderate bleeding persists beyond 6 months despite adherence to the COC and use of NSAIDs, further evaluation with pelvic ultrasound is warranted to exclude structural abnormalities. 1